Pancreatic ductal adenocarcinoma (PDAC) is a clinically challenging cancer, due to both its
late stage at diagnosis and its resistance to chemotherapy. However, recent advances in our …

Description The purpose of this American Gastroenterological Association Institute Clinical
Practice Update is to describe the indications for screening for pancreas cancer in high-risk …

The scientific data to guide the management of Peutz–Jeghers syndrome (PJS) are sparse.
The available evidence has been reviewed and discussed by diverse medical specialists in …

Importance Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with increasing
incidence. The majority of PDACs are incurable at presentation, but population-based …

Beyond breast and ovarian cancers, mutations in the BRCA1 and BRCA2 genes increase
risks for pancreatic and prostate cancers and contribute to the prevalence of these cancers …

Pancreatic cancer (PC) is an increasingly common disease worldwide. Having a better
understanding of worldwide and regional epidemiologic features and risk factors of PC is …

Background & Aims Identification and resection of successful targets, that is, T 1 N 0 M 0
pancreatic ductal adenocarcinoma (PDAC) and high-grade precursors during surveillance …

Opportunities for genetic counseling and germline BRCA1/2 (BRCA) testing are increasing
in Japan owing to cancer genomic profiling testing and companion diagnostics being …

Pancreatic ductal adenocarcinoma (PDAC) is the deadliest of all major cancer types with
most patients having advanced disease at diagnosis. Recent data from the National Cancer …

Implementation of an effective screening test requires identification of a target population.
Because of its relatively low incidence, sensitivity and specificity levels of existing …